ArticlePloS one2025
Biocompatibility and antimicrobial efficacy of iodine-supported titania nanotubes on 3D-printed Ti-6Al-4V implants.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Implant-associated infections (IAI) are a significant concern within the field of orthopedics. To develop an implant with antimicrobial properties, titania nanotubes (TNTs) supported with iodine were synthesized on 3D-printed Ti-6Al-4V implants using the electrochemical anodization (ECA) technique. This study aims to analyze the release profile of iodine and the antimicrobial efficacy and cytotoxicity of the iodine-supported TNT (I-TNTs) on the 3D-printed Ti-6Al-4V implant. 3D-printed Ti-6Al-4V samples were doped with six different iodine formulations, including four test groups containing TNT and two control groups without TNT. As printed 3D Ti-6Al-4V samples and TNTs samples without iodine were also utilized as control groups. In vitro assays were performed to assess the drug elution, cytotoxicity, and antimicrobial efficacy. All tested I-TNTs samples exhibited sustained iodine release over 28 days without an initial burst. Notably, the amount of iodine released from I-TNTs was significantly higher compared to the control group. TNTs with a higher aspect ratio (AR) and the ECA process using higher potassium iodide (KI) concentration were found to have better cumulative iodine release profiles. No cytotoxicity was observed when tested against the mouse calvaria-derived preosteoblast cell line (MC3T3-E1). The antibacterial property of the implant surface became evident within 24 hours, with complete inhibition of S. aureus and MRSA in I-TNTs samples. This innovative approach is an intriguing alternative for preventing infections on 3D-printed Ti-6Al-4V implants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.